Chemotherapy with Doxorubicin, Etoposide and Cyclophosphamide (DEC) in Ovarian Cancer Persistent after Platinum-based Treatment

Author： Zanetta G. Monico S.L. Gabriele A. Miceli D. Mangioni C.

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.32, Iss.1, 1996-01, pp. : 178-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K. Kucera E. Zeisler H. Speiser P. Reinthaller A. Sevelda P.

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite

Potential Clinical Utility of CA-125 in Responsive but Persistent Large-Volume Ovarian Cancer Following Platinum-Based Chemotherapy:

By Markman M. Kennedy A. Kim J.

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 593-595

Elsevier

Access to resources Recommend Favorite

Paclitaxel-Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study

By Kurtz J.E. Deplanque G. Duclos B. Eichler F. Giron C. Limacher J.M. Herbrecht R. Maloisel F. Oberling F. Bergerat J.P. Dufour P.

Gynecologic Oncology, Vol. 70, Iss. 3, 1998-09 ,pp. : 414-417

Elsevier

Access to resources Recommend Favorite

Phase II Study of 96-hr Continuous-Infusion Etoposide and Doxorubicin with Bolus Cyclophosphamide in Refractory Epithelial Ovarian Cancer

By Fleming G.F. Waggoner S.E. Rotmensch J. Skoog L.A. Langhauser C.

Gynecologic Oncology, Vol. 65, Iss. 1, 1997-04 ,pp. : 42-45

Elsevier

Access to resources Recommend Favorite

Markers of response to platinum-based chemotherapy in lung cancer

By Barr Martin P MacDonagh Lauren O'Byrne Kenneth J

Lung Cancer Management, Vol. 2, Iss. 3, 2013-06 ,pp. : 227-239

Future Medicine

Access to resources Recommend Favorite